Lasmiditan succinate is primarily used in the treatment of acute migraine attacks. It is particularly effective for patients who do not respond well to traditional migraine medications or those who have contraindications to triptans. The drug works by selectively targeting the 5-HT1F receptor, which helps to alleviate migraine symptoms without causing vasoconstriction, making it a safer option for individuals with cardiovascular risks. It is typically administered orally and provides relief from migraine pain, nausea, and sensitivity to light and sound. Its unique mechanism of action offers an alternative for patients seeking non-vasoconstrictive migraine relief.